Dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH 2 ) 2) was originally isolated from the skin of a South American frog (Phyllomedusa sauvagei). It shows a potent affinity and selectivity towards opioid receptors exceeding that of morphine, especially for m-opioid receptors, and possesses strong opioid activity. The smallest dermorphin sequence that demonstrates activity is the N-terminal tetrapeptide (Tyr-DAla-Phe-Gly).
3) A number of tetrapeptide analogs have already been synthesized and structure-activity relationship (SAR) studies have been performed on opioid activity, receptor affinity, and selectivity. 4, 5) Since replacement of D-Ala with D-Arg at position 2 was found to lead to a dramatic increase of activity, 6) many [D-Arg 2 ]-dermorphin derivatives have been synthesized and intensive SAR studies have also been performed. [7] [8] [9] [10] Using the tail pressure test in mice, we recently found that subcutaneous (s.c.) and oral (p.o.) administration of N a -amidino-Tyr-D-Arg-Phe-MebAla-OH (I: ADAMB), N a -1-iminoethyl-Tyr-D-Arg-Phe-MebAla-OH (II) or N a -1-iminoethyl-Tyr-D-MetO-Phe-MebAla-OH (III), achieved extremely strong and long-lasting antinociceptive activity after p.o. administration, which was superior to that of morphine. 11, 12) Although constipation is a common side effect of morphine, compound III shows a weaker costive effect. 12) However, these compounds with a strong antinociceptive activity show low oral bioavailability, which has posed a problem.
Generally, peptide pharmaceuticals show very low intestinal absorbability after p.o. administration. This is thought to be due to the presence of many functional groups that form hydrogen bonds, such as amide bonds. It may also be due to the fact that membrane permeability is low for compounds with a high molecular weight (ϾM.W. 500), or because peptides are more susceptible to various hydrolytic enzymes in the intestines. [13] [14] [15] [16] [17] [18] [19] Accordingly, to improve the intestinal absorption of peptide pharmaceuticals, various absorption enhancers, peptidase inhibitors, and methods to alter molecular structure of peptides by chemical modification have been developed, and some success has been achieved. 20, 21) Dermorphin tetrapeptide analogues are known to be highly stable against enzymatic degradation. [22] [23] [24] Considering the stability of the compound itself, the low oral bioavailability of compounds I-III was inferred to be due to low intestinal absorption. Compounds I-III have a very high water solubility and we assumed that this was related to low intestinal absorption. This led to the assumption that intestinal absorption might be improved by modifying these peptides to increase lipophilicity. Here we report on improvement of the antinociceptive activity and oral bioavailability after s.c. and p.o. administration in mice using various analogues that were synthesized to have increased lipophilicity by esterification of the C-terminal carboxyl group or acylation of the phenolic hydroxyl group on Tyr 1 of compound III (Fig. 1 ).
Chemistry
All analogues were synthesized via the solution method using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC · HCl) with 1-hydroxybenzotriazole (HOBt) as the coupling reagent.
Esterification of the C-Terminal Carboxyl Group CTerminal ester derivatives were prepared through 3ϩ1 condensation by coupling the N-terminal tripeptide segment To improve the oral bioavailability of a dermorphin tetrapeptide analog, N a a -1-iminoethyl-Tyr-D-MetO-PheMeb bAla-OH (III), 1) which has a potent analgesic activity after oral administration, various derivatives were synthesized to increase lipophilicity by esterification of the C-terminal carboxyl group and/or acylation of the phenolic hydroxyl group on Tyr 1 . Antinociceptive activity was evaluated after subcutaneous or oral administration using the mouse tail pressure test. As a result, increased antinociceptive activity after oral administration as well as an improved ED 50 Boc-Tyr-D-MetO-Phe-OH (1) with H-MebAla-OX (Chart 1). A fully protected tetrapeptide (3a-u) was treated with 90% trifluoroacetic acid (TFA) or 90% HCOOH to remove the Boc group, and then the N-terminus was 1-iminoethylated by treatment with ethyl acetimidate hydrochloride in the presence of triethylamine (TEA).
Synthesis and Antinociceptive Activity of Orally Active Opioid Peptides: Improvement of Oral Bioavailability by Esterification
O-Acylation of the Hydroxy Group on Tyrosine Derivatives with O-acylation of Tyr 1 were obtained via preparation of the tetrapeptide Boc-Tyr-D-MetO-Phe-MebAla-OBu t (5) and subsequent acylation of the phenol hydroxyl group with acid chloride; Y-COCl or carboxylic acid; Y-COOH (Chart 2). The fully protected tetrapeptide (6a-p) was treated with 90% TFA to remove the Boc group, and then the N-terminus was 1-iminoethylated.
Dual-esterification of Tyr 1 and the C-Terminus Analogues having both O-acylation and C-terminal esterification were prepared by condensation of the tripeptide Boc-Tyr-DMetO-Phe-OH (1) with H-MebAla-OX, followed by acylation with acid chloride; Y-COCl or carboxylic acid; Y-COOH (Chart 3). The fully protected tetrapeptide (8a-g) was treated with 90% TFA to remove the Boc group, and then the N-terminus was 1-iminoethylated.
All crude products were purified by reversed-phase flush column chromatography and eluted with aqueous CH 3 CN containing 0.1% acetic acid to afford the purified products (Ͼ95% purity by HPLC), which were subsequently lyophilized to give the desired peptides in powder form. The structure of each product was confirmed from the 1 H-NMR and FAB mass spectra.
Antinociceptive Assay The synthesized compounds were tested for antinociceptive activity in vivo (Tables 1-3) using the tail pressure test in mice after subcutaneous (s.c.) or oral (p.o.) administration. The percentage of the maximum possible effect (% MPE) value was measured at fixed doses (1 mg/kg s.c. and 10 mg/kg p.o.) to initially evaluate the synthesized compounds. Then, analogues with a high activity underwent determination of the ED 50 value by the method of Litchfield and Wilcoxon 25) to assess their antinociceptive activity. All values were calculated from data obtained at the time of peak effect after administration of either the peptides, or morphine. Furthermore, the ED 50 dose ratio (p.o./s.c.) was calculated and compared with that of morphine or compound III to assess oral bioavailability.
Results and Discussion
Esterification of the C-Terminal Carboxyl Group The carboxyl group located at the C-terminus of compound III is easily ionized, leading to reduced lipophilicity of the compound and substantially hindering gastrointestinal absorption. Therefore, it was expected that protection of this carboxyl group by esterification would improve bioavailability by preventing ionization and increasing lipophilicity. Since various esterases exist in the body, particularly in the intestines, it was anticipated that the appropriately esterified compound would be hydrolyzed and converted to the parent compound after intestinal absorption. Thus, esterification was expected to increase gastrointestinal absorption while maintaining a strong antinociceptive activity like that of the original compound. Accordingly, compounds 4a-u were synthesized by esterification of the C-terminal carboxyl group of compound III. Table 1 shows a comparison of the antinociceptive activity of compounds 4a-u with that of morphine. Relative oral bioavailability was also evaluated using the ED 50 dose ratio after s.c. and p.o. administration. From comparison of the ED 50 values, the antinociceptive activity of compounds 4a-u, synthesized by esterification of the C-terminal carboxyl group of compound III, was lower than that of the parent compound after both s.c. and p.o. administration. However, the ED 50 values obtained after s.c. administration of hexadecylated compound 4k and compound 4t (which has a 1Ј-ethoxycarbonyloxyethyl group 26) and is a successful example of a prodrug developed from a b-lactam antibiotic) were larger than that for compound III, although the values for p.o. administration were about the same. The ED 50 (p.o.)/ED 50 (s.c.) ratio was 10 and 17, respectively, showing improvement compared with the ratio of 39 for parent compound III. Therefore, it seems likely that esterification attenuated the antinociceptive activity, but oral antinociceptive activity was maintained at a comparable level to that of compound III as a consequence of improved oral bioavailability. As other examples of prodrugs, compound 4s with a pivaloyloxymethyl group 27) and compound 4u with a phthalidyl group, 28 ) also showed the same trend, although these compounds had a lower antinociceptive activity for after s.c. or p.o. administration than 4t.
O-Acylation of the Hydroxyl Group of Tyrosine It is well known that esterification of the phenolic hydroxyl group in morphine-related compounds, such as heroin (synthesized by acetylation of the hydroxyl group of morphine), increases their lipophilicity and allows significantly improved permeation of the blood brain barrier (BBB), that leads to severalfold augmentation of analgesic activity. 29, 30) There also is a phenolic hydroxyl group at Tyr 1 of compound III. This hydrophilic group was thought to increase water solubility and thus hinder gastrointestinal absorption. Therefore, as with esterification of the C-terminus, acylation of the hydroxyl group of Tyr was expected to improve lipophilicity and gastrointestinal absorption. Accordingly, we synthesized compounds with various acyl groups attached to the phenolic hydroxyl group of the Tyr 1 residue. Table 2 shows the antinociceptive activity and ED 50 (p.o.)/ ED 50 (s.c.) ratio of O-acylated compounds 7a-p. From comparison of the dose-activity ratios, it is apparent that the oral bioavailability of these acylated compounds (7a-p) was clearly higher than that of the parent compound, which had a value of 39. In particular, the acetylated compound 7a and the methoxycarbonylated compound 7l had values of 9 and 5, respectively, which were close to the value for morphine. These compounds showed improved dose-activity ratios and exhibited analgesic activity after oral administration that was equal to or greater than that of compound III. This was assumed to be due to the improvement of oral bioavailability. On the other hand, activity was slightly decreased after s.c. administration. This was assumed to be due to increased lipophilicity of the compound because of acylation, which may have affected diffusion of the drug from the s.c. administration site, uptake into the blood, and binding with plasma proteins.
Dualesterification at the Hydroxy Group of Tyrosine and C-Terminal Carboxyl Group Esterification of the Cterminal carboxyl group or acylation of the Tyr 1 phenolic hydroxyl group improved the oral bioavailability of some compounds. Combining the two substituents that improved oral bioavailability was expected to have an augmented effect. Therefore, to achieve further improvement, we synthesized esterified and acylated compounds 9a-g. Table 3 shows the antinociceptive activity and ED 50 (p.o.)/ ED 50 (s.c.) ratio of the esterified and acylated compounds 9a-g. Contrary to our expectations, comparison of the doseactivity ratios revealed that the antinociceptive activity of the doubly modified compounds 9a-g was not increased. However, the ED 50 value obtained after s.c. administration of compound 9c, with an acetylated phenolic hydroxyl at Tyr 1 and a 1Ј-ethoxycarbonyloxyethyl group at the C-terminal carboxyl group, was larger than that of compound III, but the ED 50 (p.o.)/ED 50 (s.c.) ratio was 11, showing an improvement from that of parent compound III (which was 39).
Comparison of the Duration of Antinociceptive Activity Figure 2 shows the time course of antinociceptive activity after s.c. administration of morphine and compound III in the mouse tail pressure test. Compound III (Fig. 2B) showed a higher dose-dependent antinociceptive activity than morphine ( Fig. 2A) . The duration of activity of compound III was over 8 h after administration of 0.25 mg/kg, but the activity of morphine ended within 4 h, even after administration of 10 mg/kg. As can be seen in Fig. 3B , compound III showed a strong dose-dependent antinociceptive effect after p.o. administration. An antinociceptive effect equivalent to 30% of MPE was even maintained at 10 h after administration of 5.0 mg/kg, whereas the effect disappeared almost completely within 6 h after 80 mg/kg of morphine (Fig. 3A) . Figure 4 shows the time course of antinociceptive activity after s.c. administration of compound 4k (Fig. 4A ) and compound 7a (Fig. 4B) , both of which showed improved absorbability. The time course of activity for compound 4k (Fig. 4A ) and compound 7a (Fig. 4B) ent compound III. Although a time lag before the onset of antinociceptive activity and prolongation of its duration were expected judging from the time necessary for metabolism of ester and acyl derivatives involving the hydrolysis of ester and acyl groups, no such effects were seen. Figure 5 shows the time course of antinociceptive activity after p.o. administration of compound 4k (Fig. 5A ) and compound 7a (Fig. 5B) . The peak antinociceptive effect of compound III after a dose of 5.0 mg/kg was around 3 h, whereas it was around 4 h for compound 4k (Fig. 5A ). The maximum %MPE for both compounds III and 4k was 65%. The maximum %MPE after administration of compound III at 2.5 mg/kg was around 40%, whereas it was about 90% for compound 7a (Fig. 5B) , and clearly showed an increase of antinociceptive activity. Therefore, after p.o. administration, compound 7a would show better absorption than compound III. In addition, the peak antinociceptive effect of compound 4k and compound 7a was seen around 5 h after administration of 2.5 mg/kg. Thus, the peak was later than for compound III and this was thought to be due to the time necessary for metabolism of the compounds, such as hydrolysis of the ester and acyl groups.
In conclusion, we synthesized various derivatives with improved lipophilicity based on N a -1-iminoethyl-Tyr-D-MetOPhe-MebAla-OH (compound III), which has a strong antinociceptive activity, by esterification of the C-terminal carboxyl group and acylation of the phenolic hydroxyl group on Tyr 1 in order to improve intestinal absorption. We then investigated the improvement of antinociceptive activity and assessed the oral bioavailability of these compounds. As a result, an increase of antinociceptive activity after was seen p.o. administration of some of the compounds. Acylation of the phenolic hydroxyl group on Tyr 1 improved absorption more than esterification of the C-terminal carboxyl group. In particular, short chain substituents such as acetyl groups (compound 7a) and methoxycarbonyl groups (compound 7l) achieved an oral bioavailability equivalent to that of morphine. However, oral bioavailability was estimated using ED 50 (p.o.)/ED 50 (s.c.) ratios in this study. In the future, there is the necessity of evaluating by the concentration measurement in blood, the membrane permeability assay using Caco-2 cell monolayer system, etc. On the other hand, when both esterification and acylation were performed (anticipating a synergistic effect), there was a significant decrease of antinociceptive activity after both s.c. and p.o. administration. In general, passive diffusion across membranes, is highly dependent on the molecular weight of a compound and if the molecular weight is too high, membrane permeability will decrease. Increasing the lipophilicity improves the BBB permeability and intestinal absorption of drugs. However, using large substituents may increase the molecular weight and reduce the water solubility, resulting in poor intestinal absorption. Some of the ester and acyl groups investigated in this study have a large enough ester moiety to markedly increase the molecular weight, so our failure to obtain the anticipated increase of absorption might be inevitable. Therefore, to achieve higher oral bioavailability, it will be necessary to use substituents with an appropriate balance between lipophilicity and water solubility, along with concepts such as the 'rule of 5' 31) or 'chemical delivery systems'. 32) The knowledge gained from this study about peptide chemical modifications and oral bioavailability will be useful for developing future oral peptidergic analgesics.
Experimental
Commercial amino acid derivatives, EDC · HCl and HOBt, were obtained from Kokusan Chemical Works, Ltd. (Aichi, Japan). Purification of the final products was achieved by flush chromatography using a reversed-phase silica gel Chromatorex ODS DM1020T from Fuji Silysia Chemical Ltd. (Aichi, Japan), which was eluted by a stepwise gradient of acetonitrile (starting from 1-5% and increasing stepwise by 1-2%) in 0.1 M acetic acid. Analytical high-pressure liquid chromatography was done on a Nucleosil 100 5C 18 column (4.6ϫ150 mm) with an Agilent 1100 HPLC system. The products were analyzed using a linear gradient of 10-90% acetonitrile in 0.1% aqueous TFA over 20 min at a flow rate of 1 ml/min and UV detection at 230 and 280 nm.
1 H-NMR spectra were recorded with a JEOL JMN-AL300 (300 MHz) spectrometer, using tetramethylsilan (TMS) as the internal standard. Mass spectra (FAB-MS) were obtained with a JEOL mass spectrometer (model JMS-700).
Method A (Coupling Procedure 1) To a solution of a carboxy component (1.0 eq), the amino component (1.1 eq), HOBt (1.1 eq) in DMF, and TEA (1 eq if the amino component was in the protonated form) were added at 0°C. Then, EDC · HCl (1.2 eq) was added to the solution at Ϫ10°C. This mixture was stirred for 30 min at Ϫ10°C and then stirred overnight at room temperature. Then the reaction mixture was diluted with EtOAc. The solution or suspension was washed with 1 N-HCl, sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was crystallized from appropriate solvents or purified by flush column chromatography.
Method B (Coupling Procedure 2) To a solution of a carboxy component (1.0 eq), HOBt (1.1 eq) in DMF (2-5% v/w), EDC · HCl (1.2 eq) was added to the solution at Ϫ10°C. This mixture was stirred for 30 min at Ϫ10°C. Then the amino component (1.1 eq) in DMF (2-5% v/w) was added at Ϫ10°C, followed by stirring overnight at room temperature. The reaction mixture was diluted with EtOAc. The solution or suspension was washed with 1 N-HCl, sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was crystallized from appropriate solvents or purified by flush column chromatography.
Method C (Esterification) A mixture of the Boc-protected amino acid (1.0 eq), alcohol (1.1 eq), and DMAP (0.1 eq) in CH 2 Cl 2 (2-5% v/w) was stirred at 0°C. Then, EDC · HCl (1.2 eq) was added to the solution. This reaction mixture was stirred for 1 h at 0°C and then stirred overnight at room temperature. The reaction mixture was subsequently concentrated in vacuo, and dissolved with EtOAc, after which the solution was washed with 1 NHCl, sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was purified by flush column chromatography.
Method D (Deprotection 1) The Boc-protected amino acid or peptide was treated with 4 N-HCl/EtOAc (1-3% v/w) for 0.5-1 h at room temperature to remove the Boc group. Ether was added to the solution and the precipitated solid was separated by filtration and dried in a vacuum desiccator over solid NaOH.
Method E (Deprotection 2) The Boc protected amino acid tert-butyl ester or the N-Boc protected peptide with C-terminal tert-butyl ester was treated with 90%-HCOOH (1-3% v/w) for 3-5 h at room temperature to remove only the Boc group. The solvent was evaporated in vacuo at 20°C. The residue was dissolved in EtOAc, then washed with sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was used for subsequent condensation without purification.
Method F (O-Acylation 1) To a solution of the protected peptide with a free hydroxy group of tyrosine (1.0 eq) in DMF (2-5% v/w), the acid chloride (1.1 eq) was added at 0°C. Then TEA (1.2 eq) was added to the solution at 0°C. This mixture was stirred for 1 h at 0°C and then stirred overnight at room temperature. Then the reaction mixture was diluted with EtOAc, after which the solution or suspension was washed with 1 N-HCl, sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was crystallized from appropriate solvents or purified by flush column chromatography.
Method G (O-Acylation 2)
To a solution of the peptide with a free hydroxy group of tyrosine (1.0 eq) in DMF (2-5% v/w), Y-COOH (1.1 eq) and DMAP (0.1 eq) were added at 0°C. Then EDC · HCl (1.2 eq) was added to the solution at 0°C, followed by stirring for 1 h at 0°C and then stirred overnight at room temperature. Subsequently, the reaction mixture was diluted with EtOAc, after which the solution or suspension was washed with 1 N-HCl, sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was crystallized from appropriate solvents or purified by flush column chromatography.
Method H (1-Iminoethylation of the N-Terminus and Final Purification)
The fully-protected peptide was treated with 90%-TFA (1-3% v/w) or 90%-HCOOH (1-3% v/w, if it was tert-butyl ester) for 1-5 h at room temperature to remove the Boc group. The reaction mixture was concentrated in vacuo, and the residue was dissolved in DMF (2-5% v/w), after which ethyl acetimidate hydrochloride (2.0 eq) and TEA (3.0 eq) were added. This solution was stirred at room temperature for 2-4 h and then the reaction mixture was concentrated in vacuo. The residue was purified by ODS chromatography with a stepwise gradient of acetonitrile (starting from 1-5% and increasing stepwise by 1-2%) in 0.1 N-acetic acid as the eluting solvent and then lyophilized to give a white powder.
Preparation of Boc-Tyr-D-MetO-Phe-OH (1) A mixture of Boc-DMetO-OH (39.8 g, 150 mmol), HCl · H-Phe-OMe (32.4 g, 150 mmol) and HOBt (22.3 g, 165 mmol) in DMF (400 ml) was stirred at 0°C. TEA (15.1 g, 150 mmol) was added, and then EDC · HCl (34.5 g, 180 mmol) was added to the solution at Ϫ10°C. This mixture was stirred for 1 h at Ϫ10°C and then stirred overnight at room temperature. Subsequently, the reaction mixture was diluted with EtOAc, and the solution was washed with 1 N-HCl, sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was solidified from EtOAc and hexane to give Boc-D-MetO-Phe-OMe (55.9 g, 87%) as a white amorphous solid.
Boc-D-MetO-Phe-OMe (42.5 g, 100 mmol) was treated with 4 N-HCl/ EtOAc (500 ml) for 30 min at room temperature to remove the Boc group. Ether was added to the solution and the precipitated solid was separated by filtration and dried in a vacuum desiccator over solid NaOH. This amine component was dissolved in DMF (750 ml) on an ice bath. To this solution was added Boc-Tyr-OH (30.9 g, 110 mmol) and HOBt (27 g, 200 mmol). Neutralization with TEA (12.1 g) was followed by addition of EDC · HCl (23.0 g, 120 mmol) at Ϫ10°C. The reaction mixture was stirred for 1 h at the same temperature, and then stirred overnight at room temperature. Subsequently, the reaction mixture was diluted with EtOAc, and the solution was washed with 1 N-HCl, sat. NaHCO 3 , and brine. The organic phase was dried over MgSO 4 , filtered, and evaporated in vacuo. The residue was solidified from EtOAc and hexane to give Boc-Tyr-D-MetO-Phe-OMe (51.4 g, 87%) as a white amorphous solid.
To a solution of Boc-Tyr-D-MetO-Phe-OMe (48.0 g, 81.4 mmol) in MeOH (400 ml), 2 N-NaOH (62 ml) was added and the mixture was stirred at room temperature for 2 h. 
N
a a -1-Iminoethyl-Tyr-D-MetO-Phe-Meb bAla-OMe (4a) As described in method H, compound 3a (2.02 g, 3.0 mmol) was treated with 90%-TFA (30 ml) for 1 h at room temperature to remove the Boc group. The reaction mixture was concentrated in vacuo, and the residue was dissolved in DMF (60 ml), and then ehtyl acetimidate hydrochloride (741 mg, 6.0 mmol) and TEA (1.25 ml, 9.0 mmol) were added. This solution was stirred at room temperature for 2 h. The crude peptide was purified by ODS chromatography with a stepwise gradient of acetonitrile (starting from 1% and increasing stepwise by 2%) in 0. 2H, m), 3.56 (3H, s), 3.52 (1H, m), 3.40 (1H, m) 48 (1H, m), 7.33-7.15 (7H, m) The animals were purchased from Japan SLC Inc. (Shizuoka, Japan) and were housed in cages (5-6 matched for weight) in a colony room. Animals were given standard food (MM-3, Japan SLC Inc.) and tap water ad libitum. The air-conditioned room was maintained at 23Ϯ2°C and 55Ϯ20% relative humidity, with a standard 12-h light-dark cycle (lights on from 6:00 to 18:00). Antinociceptive activity was examined by the tail pressure test ac-cording to the method of Sakurada et al. 35) with slight modification. In brief, mechanical pressure was applied to the base of the tail at 32 g/s using an automated tail-pressure unit (Ugo Basile, Italy). Biting or struggling behavior of the mice was used as an indication of the response threshold and only mice responding to a tail pressure of 100 to 300 g were selected for this experiment. The trial was terminated at a level of 500 g to prevent tissue damage to the tail. The meanϮS.E.M. of the pressure was plotted. To obtain the dose-response curve, the dose was plotted against the percentage of the maximum possible effect (%MPE), which was calculated as follows: %MPEϭ(P 2 ϪP 1 /500ϪP 1 )ϫ100, where P 1 is the response pressure before drug administration (g) and P 2 is the response pressure after drug administration (g). The peptides were dissolved in saline (Fuso Chemical Industries, Osaka, Japan) for administration and saline alone was used as the control. ED 50 values were obtained by the method of Litchfield and Wilcoxon 25) to compare the antinociceptive activity of the compounds. The values were calculated from data that were obtained at the time of peak effect after either peptide or morphine administration.
